1 of 1
Story summary
- A phase 3 Lancet trial in the United Kingdom found that retatrutide lowered HbA1c by 1.7–1.9 points and reduced body weight by 11.5%–15.3% over 40 weeks.
- The trial enrolled 930 adults and recorded 14 serious adverse events, two of which occurred in the placebo arm.
- Most side-effects were mild gastrointestinal symptoms that resolved quickly.
- Royal College of Physicians adviser Kath McCullough praised the findings.
- University of Cambridge specialist Marie Spreckley called for head-to-head trials.
